Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Open
Phase 3
This trial is comparing volrustomig (MEDI5752) and chemotherapy with pembrolizumab and chemotherapy. It is for people with non small cell lung cancer that has spread to another part of the body.
You pronounce volrustomig as vole-rust-oh-mig.
Recruitment start: 11 December 2023
Recruitment end: 24 December 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Tom Newsom-Davies
AstraZeneca
Last reviewed: 9 September 2025
CRUK internal database number: 19602
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
